Kazia Therapeutics ADR (ASX:KZA), (NASDAQ:KZIA) is an innovative biotechnology company focused on the development of novel treatments for cancer. Traded on the NASDAQ under the symbol KZIA, the company's portfolio includes projects aimed at addressing some of the most challenging forms of the disease, such as glioblastoma, the most common and aggressive form of brain cancer. Kazia's primary objective is to advance these treatments through clinical trials with the goal of improving patient outcomes and providing new hope to individuals and families affected by cancer. Through collaboration with leading cancer research institutions and a dedication to scientific excellence, Kazia strives to translate cutting-edge research into therapies that can make a real difference in the fight against cancer.